Buchali 1988

Methods	Randomised double blind trial.
Participants	N = 49 men with prostate cancer. Metastatic bone lesions confirmed by 99mTcEHDP bone scan and radiographs. (25 on 89Sr, 24 on placebo).
Interventions	1. 75 MBq/mo for 3 months 89Sr administered iv 2. Placebo. Follow up: 36 months.
Outcomes	Patient reported subjective pain palliation. Survival up to 2 years. Toxicity assessed at 3, 6 and 12 months.
Notes	8 patients had no pain at start of treatment, 10 patients died whilst on treatment, 0 patients withdrawn, 0 patients lost to follow up.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) Patients	Low risk	"Patients were selected randomly, and the group they were in was not uncovered earlier than one year after the start of treatment".
Blinding (performance bias and detection bias) Study researchers	Unclear risk	Not described.
Blinding (performance bias and detection bias) Outcome assessment	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Numbers described but no causes. High attrition rate.